ResMed Inc: A Significant Upside Despite The Perceived Risk (NYSE:RMD)

seekingalpha.com · 2026-09-10

ResMed (RMD) stock: why it de-rated despite 17% EPS growth. Mask/consumables revenue and key risks analyzed, with $280–$300 target.